Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Development and Validation of the CervantesPROM, a New Menopause-Specific Quality-of-Life Measure (CervantesPROM)

9 de novembro de 2026 atualizado por: Silvia Pilar González Rodríguez, Asociación Española para el Estudio de la Menopausia

Official Title Development and Psychometric Validation of the CervantesPROM, a New Patient-Reported Outcome Measure (PROM) of Health-Related Quality of Life in Women During the Peri and Postmenopause

The Cervantes Scale and its short form (Cervantes-SF) have been the reference instruments for measuring menopause-related quality of life in Spain for two decades, but they do not capture several of today's most prevalent symptoms (weight and body changes, mood lability, cognitive complaints, dyspareunia), they confound the presence or intensity of a symptom with its actual impact, and they contain socioculturally outdated items.

This study develops and psychometrically validates the CervantesPROM, a new self-administered, digital patient-reported outcome measure (PROM) of health-related quality of life for women aged 35 to 75 years in the menopausal transition and postmenopause, following Classical Test Theory and COSMIN standards. For each symptom, the instrument records separately whether it is present and how much it bothers the woman in daily life, which is the dimension scored for quality of life.

The project has three phases: item generation and content validity (Phase 1, completed with an expert panel), item reduction and psychometric validation (Phases 2A and 2B), and responsiveness (Phase 3). Reference values for the Spanish population are an objective of the linked SILVA study, which has its own registration.

Visão geral do estudo

Status

Ainda não está recrutando

Condições

Descrição detalhada

Design: observational, prospective, multicentre study conducted in Spain. No investigational product is used and the study does not modify clinical practice. Each phase starts only after a favourable opinion of the Research Ethics Committee.

Phase 1 (completed): an initial pool of 41 items was generated from existing instruments, epidemiological data and the clinical expertise of the research group, and rated by a panel of nine menopause experts for essentiality, relevance and item-domain congruence (scale-level content validity index 0.873). The resulting version 1.0 comprises 25 symptom items in 7 domains (vasomotor; sleep and energy; musculoskeletal and body-related; emotional; cognitive; genitourinary; sexual), an individualized subscale of up to 3 symptoms, and a section on impact on areas of life.

Phase 2A (item reduction): single administration of version 1.0 to 175-250 women (7 to 10 per item; operational target 250), recruited by collaborating gynaecologists in public and private settings in several Spanish provinces. Recruitment is competitive: there is no quota per investigator; the electronic case report form centrally monitors a target composition of the whole sample by age group (35-44, 45-54, 55-64 and 65-75 years: 50, 83, 67 and 50), educational level (primary or none, secondary, higher: 100, 50 and 100), menstrual status (at least 67 still menstruating with cycle changes) and symptom intensity (at least 67 mild and 67 severe). To compensate for responses excluded by the data-quality controls of the application (minimum completion time and invariant response patterns), up to 20% over-recruitment is allowed (maximum 300 women). Women currently using menopausal hormone therapy or combined hormonal contraception are excluded in this phase only, to avoid an artificial floor effect; progestogen-only methods are eligible. All recruitment is by individual invitation from an investigator who has personally checked the selection criteria, through three routes: patients during a clinic visit, patients of the investigator's own practice by a personal digital message, and women from the general population who are not patients of the investigator (for example, women accompanying a patient, relatives or women from the investigator's social or work environment). To reduce the selection bias of a purely clinical sample, the majority of participants are intended to come from the general population; the route is recorded for every participant. There is no public dissemination in this phase and participants cannot forward their access. Participants give electronic informed consent before the first question and complete the questionnaire on their own device in 15-20 minutes. Participants who separately agree are offered an optional cognitive interview of about 30 minutes after completing the questionnaire, in the clinic or by telephone, with a demonstration version that stores no answers. Verbal probing covers all 25 items; 10-12 interviews in two rounds give at least 7 women per item. Interviews are not recorded. Items are removed by a sequential procedure: non-response above 30%, low variability, inter-item correlation above 0.90 within a domain, item-total correlation below 0.30, reliability gain above 5% if deleted, and communality below 0.20 or cross-loadings in exploratory factor analysis.

Phase 2B (psychometric validation): new, independent sample of 15 to 20 women per item of the reduced version (maximum 375-500), with or without hormonal treatment, recorded as a covariate. Participants complete the reduced CervantesPROM, the Cervantes-SF, the Menopause Rating Scale II, the PHQ-8, the GAD-7, the FSFI-6 (sexually active women only) and the EQ-5D-5L with its visual analogue scale. Test-retest substudy: about 150 postmenopausal women are invited to obtain at least 100 stable women after 7-14 days.

Phase 3 (responsiveness): about 150 women who, on their physician's indication, start treatment for menopausal symptoms; the study does not intervene in the therapeutic decision. Assessments at baseline and at 3 months (reduced CervantesPROM, MRS II, EQ-5D-5L and global visual analogue scale), with a Global Rating of Change scale as anchor for the minimal important difference. Employed women who agree record absenteeism, presenteeism and interference with non-work activities once a month for three months.

Reference values for the Spanish population are an objective of the linked SILVA study (AEEM-SILVA-2026-01), with its own protocol, consent and registration; they are not part of this study.

Data protection: the application collects no direct identifiers; data are coded (pseudonymised) and stored in the European Union. Participants may separately consent to the use of their coded data in other studies on women's health, each subject to a favourable opinion of an ethics committee.

Tipo de estudo

Observacional

Inscrição (Estimado)

950

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Silvia P González Rodríguez, MD, PhD, MSc
  • Número de telefone: +34 913 502 765
  • E-mail: presidencia@aeem.es

Estude backup de contato

  • Nome: AEEM Secretariat
  • Número de telefone: +34 913 502 765
  • E-mail: aeem@aeem.es

Locais de estudo

      • Madrid, Espanha
        • Asociación Española para el Estudio de la Menopausia (AEEM), Study Coordinating Centre

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

35 anos a 75 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Fêmea

Método de amostragem

Amostra Não Probabilística

População do estudo

Women aged 35 to 75 years living in Spain and able to understand Spanish, in the menopausal transition or postmenopause. In Phases 2A to 3 they are recruited by collaborating gynaecologists in several Spanish provinces, always by individual invitation after the investigator has checked the selection criteria: patients in public and private clinical settings and, in Phase 2A, preferably women from the general population who are not patients. No premenopausal control group is recruited.

Descrição

Inclusion Criteria:

  • Women aged 35 to 75 years, living in Spain.
  • Late reproductive stage (regular cycles with a change in menstrual flow), perimenopause or postmenopause, including early menopause and premature ovarian insufficiency; or a stage not classifiable by menstrual criteria because of hysterectomy, endometrial ablation or hormonal contraception.
  • Able to understand and complete a self-administered questionnaire in Spanish.
  • Informed consent.
  • Phase 3 only: physician's indication to start treatment for menopausal symptoms (the study does not intervene in that decision).

Exclusion Criteria:

  • Regular menstrual cycles with no menstrual change and no climacteric symptoms.
  • Active cancer under oncological treatment (a history of treated cancer is not an exclusion criterion).
  • Active or decompensated severe disease, or hospital admission in the previous 3 months (stable chronic conditions such as hypertension, diabetes or hypothyroidism are not excluded).
  • Active severe psychiatric disorder that prevents understanding or completing the questionnaire (treatment with antidepressants or anxiolytics alone is not an exclusion criterion).
  • Phase 2A only: current menopausal hormone therapy or combined hormonal contraception (pill, ring or patch). Progestogen-only methods, including the levonorgestrel intrauterine system, are eligible.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: COHORT
  • Perspectivas de Tempo: PROSPECTIVE

Coortes e Intervenções

Grupo / Coorte
Phase 2A: item reduction

Women aged 35-75 years in the late reproductive stage, perimenopause or postmenopause, not using menopausal hormone therapy or combined hormonal contraception, who complete version 1.0 of the CervantesPROM once (target 250, maximum 300 including over-recruitment for data-quality exclusions). Includes an optional later cognitive interview in 10-12 women.

Phase 2B: psychometric validation

New, independent sample of women aged 35-75 years, with or without hormonal treatment, who complete the reduced CervantesPROM and the reference instruments once (15-20 per item, up to 500). Includes a test-retest subsample of about 150 invited, at least 100 stable.

Phase 3: responsiveness

About 150 women aged 35-75 years who start treatment for menopausal symptoms on their physician's indication, assessed at baseline and at 3 months; employed women may also complete a monthly work diary.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Number of CervantesPROM symptom items retained after item reduction
Prazo: Single questionnaire administration at enrollment (Phase 2A).

The number of symptom items retained in the reduced CervantesPROM after applying the prespecified sequential psychometric item-reduction procedure to the 25 items of version 1.0. The outcome is reported as a single integer representing the final number of retained items (possible range: 0-25).

Single questionnaire administration at enrollment (Phase 2A).
Comparative Fit Index (CFI) of the reduced CervantesPROM
Prazo: Single questionnaire administration at enrollment (Phase 2B).

CFI obtained from confirmatory factor analysis of the prespecified factor structure. Higher values indicate better model fit.

Single questionnaire administration at enrollment (Phase 2B).
Tucker-Lewis Index (TLI) of the reduced CervantesPROM
Prazo: Single questionnaire administration at enrollment (Phase 2B).

TLI obtained from confirmatory factor analysis of the prespecified factor structure. Higher values indicate better model fit.

Single questionnaire administration at enrollment (Phase 2B).
Root Mean Square Error of Approximation (RMSEA) of the reduced CervantesPROM
Prazo: Single questionnaire administration at enrollment (Phase 2B).

RMSEA obtained from confirmatory factor analysis of the prespecified factor structure. Lower values indicate better model fit.

Single questionnaire administration at enrollment (Phase 2B).
Standardized Root Mean Square Residual (SRMR) of the reduced CervantesPROM
Prazo: Single questionnaire administration at enrollment (Phase 2B).

SRMR obtained from confirmatory factor analysis of the prespecified factor structure. Lower values indicate better model fit.

Single questionnaire administration at enrollment (Phase 2B).
Cronbach's alpha of the reduced CervantesPROM total score
Prazo: Single questionnaire administration at enrollment (Phase 2B).

Cronbach's alpha coefficient calculated to assess the internal consistency of the reduced CervantesPROM total score.

Single questionnaire administration at enrollment (Phase 2B).
McDonald's omega of the reduced CervantesPROM total score
Prazo: Single questionnaire administration at enrollment (Phase 2B).

McDonald's omega coefficient calculated to assess the internal consistency of the reduced CervantesPROM total score.

Single questionnaire administration at enrollment (Phase 2B).

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Percentage of cognitive interview item assessments indicating comprehension difficulties
Prazo: One optional interview of about 30 minutes, within 2 weeks after completing the questionnaire (Phase 2A)

The percentage of item-level assessments rated as "some difficulty" or "not understood" during structured cognitive interviews. Each participant evaluates 2-3 CervantesPROM items. The percentage ranges from 0% to 100%, with higher values indicating more comprehension difficulties (worse comprehensibility). This is a categorical assessment, not a questionnaire scale score. Verbal probing of all 25 items in 10-12 women (two rounds; at least 7 women per item): comprehension, distinction between bother and symptom intensity, response options, recall period and instructions. Comprehension problems are recorded per item and classified independently by two researchers.

One optional interview of about 30 minutes, within 2 weeks after completing the questionnaire (Phase 2A)
Test-retest reliability and measurement error
Prazo: Baseline and 7 to 14 days (Phase 2B)

Intraclass correlation coefficient and standard error of measurement between two administrations of the CervantesPROM in stable postmenopausal participants.

Baseline and 7 to 14 days (Phase 2B)
Percentage of prespecified construct validity hypotheses confirmed
Prazo: Single questionnaire administration at enrollment (Phase 2B).

Percentage of prespecified construct validity hypotheses supported by the observed correlations between the reduced CervantesPROM and reference measures of menopausal symptoms, general health, mood and sexual function. Each hypothesis is evaluated against its prespecified direction and magnitude. The outcome ranges from 0% to 100%, with higher percentages indicating stronger evidence of construct validity. Construct validity is considered adequate when at least 75% of the hypotheses are confirmed.

Single questionnaire administration at enrollment (Phase 2B).
Standardized Response Mean (SRM) of the CervantesPROM total score
Prazo: Baseline and 3 months (Phase 3).

SRM calculated as the mean change in the CervantesPROM total score from baseline to 3 months divided by the standard deviation of individual change scores. CervantesPROM scores range from 0 to 100, with higher scores indicating greater symptom-related burden.

Baseline and 3 months (Phase 3).
Work productivity loss associated with menopausal symptoms
Prazo: Monthly for 3 months (Phase 3)

Days of absenteeism, presenteeism and interference with non-work activities recorded monthly by employed participants.

Monthly for 3 months (Phase 3)
Anchor-based minimal important difference (MID) in the CervantesPROM total score
Prazo: Baseline and 3 months (Phase 3).

Minimal important difference in the CervantesPROM total score estimated using the Global Rating of Change scale at 3 months as an external anchor. The estimate will be expressed in CervantesPROM score points on a 0-100 scale.

Baseline and 3 months (Phase 3).

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Silvia P. González Rodríguez, MD, PhD, MSc, Asociación Española para el Estudio de la Menopausia

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de dezembro de 2026

Conclusão Primária (Estimado)

1 de dezembro de 2027

Conclusão do estudo (Estimado)

1 de dezembro de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

4 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

9 de novembro de 2026

Primeira postagem (Real)

12 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

12 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

9 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • AEEM-CERVANTESPROM-2026-01

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

Individual participant data will not be shared. Data are coded and kept by the sponsor; the anonymised dataset will be kept for verification for a maximum of five years after publication of the results and then securely deleted. Coded data of participants who separately consent may be kept up to ten years and reused only in other studies on women's health with a prior favourable opinion of an ethics committee. Results will be published in aggregate form, following the COSMIN reporting guideline.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .